Biosyent Inc. · TSXV:RX
Biosyent — Q2 2026 Earnings Presentation
22 slides from Biosyent's earnings presentation, Aug 20, 2026
Slide 1: BioSyent Inc. Q2/H1 2026 Results
BioSyent BioSyentInc. Inc. Q4 / FY 2023 Q2/H1 2026 Results Results MARCH AUGUST13, 20,2024 2026 PRESENTED BY: RENÉ GOEHRUM PRESENTED BY: RENÉ GOEHRUM PRESIDENT AND CEO PRESIDENT AND CEO 1 | www.biosyent.com | TSXV: RX 1 | www.biosyent.com | TSXV: RX
Slide 2: Disclaimer
DISCLAIMER This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements
Slide 3: Specialty Pharmaceuticals and Oral Health Products
Specialty Pharmaceuticals WHAT Oral Health Products We bring proven healthcare products to patients and their providers. WHERE 3 www.biosyent.com | TSXV: RX | OTC: BIOYF
Slide 4: 4 | www.biosyent.com | TSXV: RX | www.biosyent.com | TSXV: RX
4 | www.biosyent.com | TSXV: RX 4 | www.biosyent.com | TSXV: RX
Slide 5: Q2/H1 Sales Summary
Q2/H1 Sales Summary ($) (CAD 000’s) Q2 2026 Q2 2025 Q1 ‘26 vs. H1 2026 H1 2025 H1 ‘26 vs. Q1 ’25 (%) H1 ‘25 (%) Pharmaceutical 11,110 9,773 +14% 21,913 20,468 +7% Oral Health1 8,224 - n/a 11,209 - n/a Insecticides 538 406 +32% 658 691 (5%) Total Company 19,873 10,179 +95% 33,781 21,158 +60% 1. Oral
Slide 6: Q2 Results Comparison
BioSyent Inc. | Q1 Results Comparison Q2 Results Comparison Metric Q2 2024 Q2 2025 Q2 2026 vs. Q2 2024 vs. Q2 2025 Revenue $8.94M $10.18M $19.87M (Net Revenues) +14% +95% EBITDA† $2.05M $2.76M $4.98M +35% +80% NIAT $1.58M $2.02M $2.85M +28% +41% Fully Diluted EPS $0.13 $0.18 $0.25 +31% +39% ROE (TTM
Slide 7: H1 Results Comparison
BioSyent Inc. | Q1 Results Comparison H1 Results Comparison Metric H1 2024 H1 2025 H1 2026 vs. H1 2024 vs. H1 2025 Revenue $16.68M $21.16M $33.78M (Net Revenues) +27% +60% EBITDA† $4.25M $5.96M $8.62M +40% +45% NIAT $3.35M $4.34M $5.19M +30% +20% Fully Diluted EPS $0.28 $0.38 $0.45 +33% +19% 7 | www
Slide 8: Fully Diluted Earnings per Share (TTM)
Fully Diluted Earnings per Share (TTM) 64 0.85 TTM and Quarterly Fully Diluted EPS (CAD) 0.90 63 Consecutive Consecutive 0.80 Profitable Quarters Profitable Quarters 0.72 0.70 0.60 to Q2 2026 to Q1 2026 0.60 TTM Jun 30, 2026 Adjusted EPS: $0.89 0.50 vs. $0.72 TTM Jun 30, 2025 0.40 0.30 0.20 0.23 0.2
Slide 9: Acquisition of Oral Science – March 1, 2026
Acquisition of Oral Science – March 1, 2026 New BioSyent Oral Health Business Unit $25.5M upfront purchase price (including $6.3M working capital) + $1.85M paid for excess working capital + performance earn out + royalties on future sales of 1 product <6x EBITDA implied purchase multiple 9 | www
Slide 10: Balance Sheet & Income Statement Impact of Acquisition
Balance Sheet & Income Statement Impact of Acquisition* Balance Sheet Provisional Purchase Price Allocation Amount Working capital $8,284,619 Property and equipment 791,813 Intangible assets 19,083,333 Goodwill 3,796,739 Lease liability (475,357) Net assets acquired $31,481,647 Income Statement $250
Slide 11: Going Forward
Going Forward • Continue growth investment in pharmaceutical + oral health platforms • Expand ex-Canada revenue on both platforms 11 | www.biosyent.com | TSXV: RX 11 | www.biosyent.com | TSXV: RX
Slide 12: YTD 2026 Highlights
YTD 2026 Highlights Mar 13, 2026: Paid quarterly dividend of $0.055/share (+10% increase vs. 2025) Jun 15, 2026: Paid quarterly dividend of $0.055/share Aug 20, 2026: Quarterly dividend of $0.055/share declared YTD June 30, 2026: 218,500 shares repurchased and cancelled under NCIB Apr 2026
Slide 13: | www.biosyent.com | TSXV: RX
13 | www.biosyent.com | TSXV: RX
Slide 14: THYCONVI - Product Overview
THYCONVI - Product Overview THYCONVI will be the first & only stable oral solution formulation for levothyroxine available in Canada, which provides convenience through flexible accurate dosing of levothyroxine to children & adults About THYCONVI: THYCONVI Benefits: • THYCONVI is an oral solution of
Slide 15: Most recommended iron supplement in Canada
Most recommended iron supplement in Canada - pharmacists and physicians - 11 consecutive years(1) Continued innovation and expansion of FeraMAX® product line for iron health (1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2026 Survey on OTC Counselling and Recomm
Slide 16: Growth Drivers
Growth Drivers Thyconvi® - 2027 launch Oral health FeraMAX® Pd Platform – Life Cycle Strategy In development Acquisition and in-licensing 16 | www.biosyent.com | TSXV: RX
Slide 17: Geopolitics, Trade and Economy
Geopolitics, Trade and Economy Uncertainty Armed conflicts Tariffs / Counter-Tariffs Inflationary impacts Transportation Supply Chains Cost of Goods Consumer Behaviour 17 | www.biosyent.com | TSXV: RX
Slide 18: Strong Balance Sheet + Cash Generation
Strong Balance Sheet + Cash Generation Supports Ongoing Portfolio Opportunities (CAD 000,000’s) Dec 31, 2025 Mar 1, 2026 Jun 30, 2026 (Acquisition Closing Date) Cash and GICs 31.9 17.2 12.2 Non-cash Working Capital 4.0 8.2 7.8 Non-current Assets 6.4 29.6 28.6 (Short Term Debt)(1) - (8.0) (2.0) (Non-
Slide 19: Capital Allocation linked to Strategy
Capital Allocation linked to Strategy First use of capital is to generate revenue/profit growth & portfolio diversification. Capital-Light, Cash- Generating Business Quarterly Dividends Model $8.1 M to Date Q4’22 – Q3’26 Share Buybacks $26.5 M to Date 3.4 million shares repurchased since 2018 •7 new
Slide 20: Stock Information
Stock Information As at August 18, 2026 Exchange & Trading Symbol 0% TSXV: RX Aug 18, 2026 Closing Stock Price (CAD) (TSXV): $14.60 52 Week Hi/Low (TSXV): $15.80 / $10.65 Issued Common Shares: 11,483,849 Treasury – RSU Shares in Trust (175,014) Outstanding Common Shares: 11,308,835 Options Outstandi
Slide 21: Well Capitalized. Profitable. Growth Assets.
WELL CAPITALIZED. PROFITABLE. GROWTH ASSETS. LONG-TERM COMPOUNDING TRACK RECORD. 21 | www.biosyent.com| |TSXV: www.biosyent.com TSXV:RXRX
Slide 22: Reconciliation of EBITDA to NIAT
Reconciliation of EBITDA to NIAT †EBITDA is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA a